Healthy Subjects Clinical Trial
Official title:
A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects
Verified date | May 2019 |
Source | MedImmune LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to assess the safety and tolerability of MEDI9314 in healthy adult subjects
Status | Completed |
Enrollment | 44 |
Est. completion date | June 12, 2017 |
Est. primary completion date | November 17, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Written informed consent. 2. Age 18 through 50 years at the time of screening. 3. Female subjects must be of non-childbearing potential. 4. Nonsterilized males who are sexually active with a female partner of childbearing potential must use condom and spermicide. 5. Body mass index of 19.0 through 32.0 kg/m2 at screening. 6. No clinically significant abnormality on the basis of medical/medication history or physical examination. 7. Negative drugs of abuse (DOA). 8. Able and willing to comply with the requirements of the protocol and complete the study until the end of the safety follow up period. 9. For the Japanese Cohort, both of the subject's parents and both sets of grandparents must be Japanese. Exclusion Criteria: 1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results. 2. Concurrent enrollment in another clinical study involving any treatment. 3. Individuals who are legally institutionalized. 4. Receipt of > 2 marketed or investigational biologic agents. 5. Receipt of an investigational biologic agent within 4 months or 5 half-lives prior to screening, whichever is longer. 6. Receipt of any investigational non biologic agent within 3 months or 5 half lives prior to screening, whichever is longer. 7. Use of any medication (prescription or over the counter, including herbal remedies) within 14 days or 5 half lives of Day 1, whichever is longer, unless in the opinion of the investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety. 8. Known history of allergy or reaction to any component of the investigational product formulation. 9. History of anaphylaxis following any biologic therapy. 10. Any clinically relevant abnormal findings in physical examination ECG, vital signs, and laboratory parameters. 11. Positive tuberculosis (TB) test (QuantiFERON®-TB Gold In-tube). 12. Positive hepatitis B surface antigen, hepatitis C virus antibody or HIV test at screening. 13. Receipt of live attenuated vaccines 30 days prior to the date of screening. 14. Where donation of blood or blood products was in excess of 500 mL within an 8-week period in the 3 months prior to screening. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Research Site | Harrow | |
United States | Research Site | Glendale | California |
Lead Sponsor | Collaborator |
---|---|
MedImmune LLC |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any AE that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug and up to Day 240. | From the start of study drug administration upto Day 240 | |
Primary | Number of Participants With Electrocardiogram Abnormalities Reported as TEAEs | TEAEs observed in participants with clinically significant ECG abnormalities were reported. | From the start of study drug administration upto Day 240 | |
Primary | Number of Participants With Vital Signs Abnormalities Reported as TEAEs | Vital sign parameters included blood pressure, heart rate, and temperature. TEAEs observed in participants with clinically significant vital signs abnormalities were reported. | From the start of study drug administration upto Day 240 | |
Primary | Number of Participants With Physical Examination Abnormalities Reported as TEAEs | Adverse events observed in participants with clinically significant physical abnormalities were assessed. | From the start of study drug administration upto Day 240 | |
Primary | Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs | An abnormal laboratory finding which required an action or medical intervention by the investigator, or a finding judged by the investigator as medically significant should be reported as an adverse event. Laboratory evaluation (haematology, serum chemistry and urinalysis) of blood and urine samples were performed. | From the start of study drug administration upto Day 240 | |
Primary | Number of Participants With TEAEs Related to Injection Site Reactions | Adverse events of special interest observed in participants with clinically significant injection site reaction were assessed. | From the start of study drug administration upto Day 240 | |
Secondary | Area Under the Serum Drug Concentration Versus Time Curves From Zero to Infinity (AUC 0-inf) of MEDI9314 | The area under the serum drug concentration versus time curves from zero to infinity of MEDI9314. | Day 1 (predose); at the end of infusion (for IV groups); 24, 48, 72, and 96 hours post dose; and on Days 8, 10, 15, 22, 29, 36, 43, 57, 85, 113, 141, 197, and 240 | |
Secondary | Area Under the Serum Drug Concentration Versus Time Curve, to Last Quantifiable Time Point (AUClast) | The area under the serum drug concentration versus time curve, to last quantifiable time point of MEDI9314. | Day 1 (predose); at the end of infusion (for IV groups); 24, 48, 72, and 96 hours post dose; and on Days 8, 10, 15, 22, 29, 36, 43, 57, 85, 113, 141, 197, and 240 | |
Secondary | Maximum Observed Serum Drug Concentration (Cmax) of MEDI9314 | The maximum observed serum drug concentration of MEDI9314. | Day 1 (predose); at the end of infusion (for IV groups); 24, 48, 72, and 96 hours post dose; and on Days 8, 10, 15, 22, 29, 36, 43, 57, 85, 113, 141, 197, and 240 | |
Secondary | Time to Maximum Observed Serum Drug Concentration (Tmax) of MEDI9314 | The time to maximum observed serum drug concentration of MEDI9314. | Day 1 (predose); at the end of infusion (for IV groups); 24, 48, 72, and 96 hours post dose; and on Days 8, 10, 15, 22, 29, 36, 43, 57, 85, 113, 141, 197, and 240 | |
Secondary | Terminal Phase Elimination Half-life (t1/2) of MEDI9314 | Terminal phase elimination half-life of MEDI9314 | Day 1 (predose); at the end of infusion (for IV groups); 24, 48, 72, and 96 hours post dose; and on Days 8, 10, 15, 22, 29, 36, 43, 57, 85, 113, 141, 197, and 240 | |
Secondary | Serum Concentrations of MEDI9314 | Baseline indicates the last assessment prior to first dose. For this study, the lower limit of quantification (LLOQ) for MEDI9314 serum concentrations were 19.53 µg/mL. Where serum concentrations were below this value, a serum concentration of 9.770 µg/mL was imputed. | Baseline (Day 1 [predose]) and Day 240 | |
Secondary | Number of Participants Positive for Anti-Drug Antibodies to MEDI9314 | Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9314. The number of participants with positive serum antibodies to MEDI9314 were presented. | Baseline (Day 1 [predose]) and Day 240 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |